TY - JOUR
T1 - Cytomegalovirus Infections of the Stem Cell Transplant Recipient and Hematologic Malignancy Patient
AU - Pande, Anupam
AU - Dubberke, Erik R.
N1 - Funding Information:
Disclosure Statement: E.R. Dubberke has research support from Pfizer, Merck & Company, Rebiotix, Sanofi and serves as consultant for Pfizer, Merck and Company, Rebiotix, Sanofi, Synthetic Biologics, Valneva, and Aerobiotix.
Funding Information:
Disclosure Statement: E.R. Dubberke has research support from Pfizer, Merck & Company, Rebiotix, Sanofi and serves as consultant for Pfizer, Merck and Company, Rebiotix, Sanofi, Synthetic Biologics, Valneva, and Aerobiotix. Disclosure Statement: E.R. Dubberke has research support from Pfizer, Merck & Company, Rebiotix, Sanofi and serves as consultant for Pfizer, Merck and Company, Rebiotix, Sanofi, Synthetic Biologics, Valneva, and Aerobiotix.
Publisher Copyright:
© 2019 Elsevier Inc.
PY - 2019/6
Y1 - 2019/6
N2 - Cytomegalovirus (CMV) may no longer be the menace that plagues stem cell transplant outcomes, owing to marked improvements in transplantation techniques and methods of prophylaxis. However, it still remains a common and morbid problem for recipients of stem cell transplant and patients with certain hematologic malignancies. This article discusses the epidemiology and risk factors of CMV infection and disease, associated morbidity and mortality, diagnosis, and clinical features of clinical syndromes associated with CMV and the principles of management of CMV, with special attention to resistant CMV as it pertains to infectious disease specialists.
AB - Cytomegalovirus (CMV) may no longer be the menace that plagues stem cell transplant outcomes, owing to marked improvements in transplantation techniques and methods of prophylaxis. However, it still remains a common and morbid problem for recipients of stem cell transplant and patients with certain hematologic malignancies. This article discusses the epidemiology and risk factors of CMV infection and disease, associated morbidity and mortality, diagnosis, and clinical features of clinical syndromes associated with CMV and the principles of management of CMV, with special attention to resistant CMV as it pertains to infectious disease specialists.
KW - Antiviral agents
KW - Cytomegalovirus
KW - Resistance
KW - Stem cell transplant
UR - http://www.scopus.com/inward/record.url?scp=85063579760&partnerID=8YFLogxK
U2 - 10.1016/j.idc.2019.02.008
DO - 10.1016/j.idc.2019.02.008
M3 - Review article
C2 - 30940460
AN - SCOPUS:85063579760
SN - 0891-5520
VL - 33
SP - 485
EP - 500
JO - Infectious disease clinics of North America
JF - Infectious disease clinics of North America
IS - 2
ER -